Eleni Nitsa Zuppas
Known title: President & Chief of StaffCIK: 0001636653
Associated companies
Transaction History
| VEEV | ▲ Buy | Option Exercise | 2,181 | $0 | 10/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 1,110 | $313K | 10/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,180 | $0 | 7/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,498 | $0 | 4/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 3,464 | $598K | 4/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 7,500 | $0 | 4/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 538 | $93K | 4/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 581 | $130K | 1/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,498 | $0 | 1/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 6,000 | $813K | 10/7/2025 | View on chart |
| VEEV | ▼ Sell | Open Market | 6,000 | $1.8M | 10/7/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 761 | $223K | 10/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,498 | $0 | 10/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,498 | $0 | 7/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 539 | $152K | 7/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 474 | $108K | 4/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,324 | $0 | 4/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,323 | $0 | 1/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 517 | $109K | 1/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 672 | $140K | 10/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,324 | $0 | 10/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,324 | $0 | 7/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 680 | $157K | 4/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,620 | $0 | 4/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 3,000 | $406K | 1/12/2024 | View on chart |
| VEEV | ▼ Sell | Open Market | 3,000 | $614K | 1/12/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 4,350 | $589K | 1/9/2024 | View on chart |
| VEEV | ▼ Sell | Open Market | 4,350 | $838K | 1/9/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,619 | $0 | 1/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,620 | $0 | 10/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,620 | $0 | 7/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 561 | $111K | 7/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,324 | $0 | 4/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,323 | $0 | 1/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,324 | $0 | 10/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,324 | $0 | 7/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 458 | $93K | 7/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 727 | $0 | 4/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 252 | $55K | 4/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 728 | $0 | 1/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 288 | $74K | 1/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 727 | $0 | 10/1/2021 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 292 | $84K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus
Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.